Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Peptide-loaded dendritic-cell vaccination followed by treatment interruption for chronic HIV-1 infection: a phase 1 trial.

Journal of medical virology - 1 Jun 2006

Ide Fuyuaki, Nakamura Tetsuya, Tomizawa Mariko, Kawana-Tachikawa Ai, Odawara Takashi, Hosoya Noriaki, Iwamoto Aikichi

Abstract excerpt

Immune response enhanced by therapeutic HIV-1 vaccine may control viral proliferation after discontinuation of highly active antiretroviral therapy (HAART). Although which strategies for therapeutic vaccination are feasible remains controversial, application of dendritic cells (DCs) as a vaccine adjuvant represents a promising approach to improving deteriorated immune function in HIV-1-infected individuals. The...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antiretroviral Therapy, Highly Active
Share to CD4 Lymphocyte Count

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Chronic Disease

Share to Dendritic Cells

Share to Epitopes, T-Lymphocyte

Share to HIV Antigens

Share to Immunotherapy

Share to T-Lymphocytes, Cytotoxic

Source

Identifiers

PMID: 16628588
DOI: 10.1002/jmv.20612

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Peptide-loaded dendritic-cell vaccination followed by treatment interruption for chronic HIV-1 infection: a phase 1 trial.PMID 16628588Read ↗

Phenotypic and functional characteristics of HIV-specific CD8 T cells and gag sequence variability after autologous dendritic cells based therapeutic vaccine.Semantic proximity Read ↗

Characterization of functional and phenotypic changes in anti-Gag vaccine-induced T cell responses and their role in protection after HIV-1 infection.Semantic proximity Read ↗

PD-1 blockade enhances HIV-1 vaccine-induced CD8⁺ T-cell responses in PWH early ART-treatedSemantic proximity Read ↗

In vitro priming recapitulates in vivo HIV-1 specific T cell responses, revealing rapid loss of virus reactive CD4 T cells in acute HIV-1 infection.Semantic proximity Read ↗

ART-Treated Patients Exhibit an Adaptive Immune Response against the HFVAC Peptides, a Potential HIV-1 Therapeutic Vaccine (Provir/Latitude45 Study).Semantic proximity Read ↗

Vaccine-induced gag-specific T cells are associated with reduced viremia after HIV-1 infection.Semantic proximity Read ↗

Autologous dendritic cell vaccination against HIV-1 induces changes in natural killer cell frequency, phenotype and functionalitySemantic proximity Read ↗

Preservation of T cell proliferation restricted by protective HLA alleles is critical for immune control of HIV-1 infection.Semantic proximity Read ↗

Th1/Th2 cytokine responses following HIV-1 immunization in seronegative volunteers. The AIDS Vaccine Evaluation Group.Semantic proximity Read ↗

Induction of HIV-specific T cell responses using αDC1 pulsed with conserved HIV-1 peptidesSemantic proximity Read ↗

Will we be able to 'spot' an effective HIV-1 vaccine?Semantic proximity Read ↗

Loading dendritic cells from HIV-1 infected patients with PLA-p24 nanoparticles or MVA expressing HIV genes induces HIV-1-specific T cell responsesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.